Generics North America (NAFTA) Industry Guide_2017

mli0157 MarketLine 28 February, 2017 67 pages

Select License

Report Description
Table of Contents
Related Reports

Summary

The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the NAFTA generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.

- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of $110.2 billion in 2016.The Mexico was the fastest growing country, with a CAGR of 13.7% over the 2012-16 period.

- Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of $99.7 billion in 2016. This was followed by Mexico and Canada, with a value of $6.3 and $4.2 billion, respectively.

- The US is expected to lead the generics industry in the NAFTA bloc, with a value of $141.2 billion in 2021, followed by Mexico and Canada with expected values of $10.1 and $4.9 billion, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the NAFTA generics market

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market

- Leading company profiles reveal details of key generics market players’ NAFTA operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume

- Compares data from the US, Canada and Mexico, alongside individual chapters on each country

Reasons to buy

- What was the size of the NAFTA generics market by value in 2016?

- What will be the size of the NAFTA generics market in 2021?

- What factors are affecting the strength of competition in the NAFTA generics market?

- How has the market performed over the last five years?

- Who are the top competitors in the NAFTA generics market?

Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
NAFTA Generics
Industry Outlook
Generics in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Mexico
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

List of Tables

1Table 1: NAFTA countries generics industry, revenue ($bn), 2012-21
2Table 2: NAFTA countries generics industry, revenue ($bn), 2012-16
3Table 3: NAFTA countries generics industry forecast, revenue ($bn), 2016-21
4Table 4: Canada generics market value: $ billion, 2012–16
5Table 5: Canada generics market volume: % of total pharma volume, 2012–16
6Table 6: Canada generics market geography segmentation: $ billion,2016
7Table 7: Canada generics market value forecast: $ billion, 2016–21
8Table 8: Canada generics market volume forecast: % of total pharma volume, 2016–21
9Table 9: Canada size of population (million), 2012–16
10Table 10: Canada gdp (constant 2005 prices, $ billion), 2012–16
11Table 11: Canada gdp (current prices, $ billion), 2012–16
12Table 12: Canada inflation, 2012–16
13Table 13: Canada consumer price index (absolute), 2012–16
14Table 14: Canada exchange rate, 2012–16
15Table 15: Mexico generics market value: $ billion, 2012–16
16Table 16: Mexico generics market volume: % of total pharma volume, 2012–16
17Table 17: Mexico generics market geography segmentation: $ billion,2016
18Table 18: Mexico generics market value forecast: $ billion, 2016–21
19Table 19: Mexico generics market volume forecast: % of total pharma volume, 2016–21
20Table 20: Mexico size of population (million), 2012–16
21Table 21: Mexico gdp (constant 2005 prices, $ billion), 2012–16
22Table 22: Mexico gdp (current prices, $ billion), 2012–16
23Table 23: Mexico inflation, 2012–16
24Table 24: Mexico consumer price index (absolute), 2012–16
25Table 25: Mexico exchange rate, 2012–16
26Table 26: United States generics market value: $ billion, 2012–16
27Table 27: United States generics market volume: % of total pharma volume, 2012–16
28Table 28: United States generics market geography segmentation: $ billion,2016
29Table 29: United States generics market value forecast: $ billion, 2016–21
30Table 30: United States generics market volume forecast: % of total pharma volume, 2016–21
31Table 31: United States size of population (million), 2012–16
32Table 32: United States gdp (constant 2005 prices, $ billion), 2012–16
33Table 33: United States gdp (current prices, $ billion), 2012–16
34Table 34: United States inflation, 2012–16
35Table 35: United States consumer price index (absolute), 2012–16
36Table 36: United States exchange rate, 2012–15
37Table 37: Apotex, Inc.: key facts
38Table 38: Mylan Inc.: key facts
39Table 39: Mylan Inc.: key financials ($)
40Table 40: Mylan Inc.: key financial ratios
41Table 41: Sandoz International GmbH: key facts
42Table 42: Teva Pharmaceutical Industries Limited: key facts
43Table 43: Teva Pharmaceutical Industries Limited: key financials ($)
44Table 44: Teva Pharmaceutical Industries Limited: key financial ratios
45Table 45: Allergan plc: key facts
46Table 46: Allergan plc: key financials ($)
47Table 47: Allergan plc: key financial ratios

List of Figures

1Figure 1: NAFTA countries generics industry, revenue ($bn), 2012-21
2Figure 2: NAFTA countries generics industry, revenue ($bn), 2012-16
3Figure 3: NAFTA countries generics industry forecast, revenue ($bn), 2016-21
4Figure 4: Canada generics market value: $ billion, 2012–16
5Figure 5: Canada generics market volume: % of total pharma volume, 2012–16
6Figure 6: Canada generics market geography segmentation: % share, by value,2016
7Figure 7: Canada generics market value forecast: $ billion, 2016–21
8Figure 8: Canada generics market volume forecast: % of total pharma volume, 2016–21
9Figure 9: Forces driving competition in the generics market in Canada,2016
10Figure 10: Drivers of buyer power in the generics market in Canada,2016
11Figure 11: Drivers of supplier power in the generics market in Canada,2016
12Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada,2016
13Figure 13: Factors influencing the threat of substitutes in the generics market in Canada,2016
14Figure 14: Drivers of degree of rivalry in the generics market in Canada,2016
15Figure 15: Mexico generics market value: $ billion, 2012–16
16Figure 16: Mexico generics market volume: % of total pharma volume, 2012–16
17Figure 17: Mexico generics market geography segmentation: % share, by value,2016
18Figure 18: Mexico generics market value forecast: $ billion, 2016–21
19Figure 19: Mexico generics market volume forecast: % of total pharma volume, 2016–21
20Figure 20: Forces driving competition in the generics market in Mexico,2016
21Figure 21: Drivers of buyer power in the generics market in Mexico,2016
22Figure 22: Drivers of supplier power in the generics market in Mexico,2016
23Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico,2016
24Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico,2016
25Figure 25: Drivers of degree of rivalry in the generics market in Mexico,2016
26Figure 26: United States generics market value: $ billion, 2012–16
27Figure 27: United States generics market volume: % of total pharma volume, 2012–16
28Figure 28: United States generics market geography segmentation: % share, by value,2016
29Figure 29: United States generics market value forecast: $ billion, 2016–21
30Figure 30: United States generics market volume forecast: % of total pharma volume, 2016–21
31Figure 31: Forces driving competition in the generics market in the United States,2016
32Figure 32: Drivers of buyer power in the generics market in the United States,2016
33Figure 33: Drivers of supplier power in the generics market in the United States,2016
34Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States,2016
35Figure 35: Factors influencing the threat of substitutes in the generics market in the United States,2016
36Figure 36: Drivers of degree of rivalry in the generics market in the United States,2016
37Figure 37: Mylan Inc.: revenues & profitability
38Figure 38: Mylan Inc.: assets & liabilities
39Figure 39: Teva Pharmaceutical Industries Limited: revenues & profitability
40Figure 40: Teva Pharmaceutical Industries Limited: assets & liabilities
41Figure 41: Allergan plc: revenues & profitability
42Figure 42: Allergan plc: assets & liabilities